Dimerix Limited (ASX:DXB)
0.2100
+0.0050 (2.44%)
Oct 21, 2026, 4:10 PM AEDT
Dimerix Revenue
In the fiscal year ending June 30, 2026, Dimerix had annual revenue of 6.35M AUD with 13.73% growth. Dimerix had revenue of 4.24M in the half year ending June 30, 2026, a decrease of -48.70%. That makes Dimerix the 40,330th largest company in the world by revenue and 779th in Australia.
Revenue
6.35M
Revenue Growth
+13.73%
P/S Ratio
19.84
Revenue / Employee
423.59K
Employees
15
Market Cap
126.08M
Revenue by Geography
- U.S.A 3.44M 79.0%
- U.K 543.60K 12.5%
- Japan 223.23K 5.1%
- Singapore 116.91K 2.7%
- Dubai 29.82K 0.7%
Fiscal year ended Jun 30, 2026 See the full Dimerix breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 6.35M | 767.08K | 13.73% |
| Jun 30, 2025 | 5.59M | -2.81M | -33.43% |
| Jun 30, 2024 | 8.39M | 8.36M | 22,712.87% |
| Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
| Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BLS Pharmaceuticals | 73.91M |
| Neurizon Therapeutics | 17.59M |
| Actinogen Medical | 12.67M |
| Orthocell | 11.41M |
| Recce Pharmaceuticals | 9.47M |
| Alterity Therapeutics | 3.61M |
| Prescient Therapeutics | 3.45M |
| Nyrada | 2.01M |
Dimerix News
- 4 weeks ago - Dimerix Slides: Investor presentation - Filings
- 5 weeks ago - Dimerix Slides: Investor presentation - Filings
- 6 weeks ago - Dimerix Slides: Investor presentation - Filings
- 6 weeks ago - DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES - PRNewsWire
- 1 month ago - Dimerix Annual report: H2 2026 - Filings
- 2 months ago - Dimerix Slides: Investor presentation - Filings
- 2 months ago - Dimerix Slides: Investor presentation - Filings
- 4 months ago - DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES - PRNewsWire